To explore the effect of Xinkang capsules in patients with stable angina pectoris(SAP) of coronary atherosclerotic heart disease(CHD).
A total of 106 CHD-SAP patients with Qi and Yin deficiency and blood stasis syndrome admitted to our hospital from February 2023 to January 2025 were randomly divided into the control group(treated with conventional western medicine) and the combined group(combined with Xinkang capsules) by simple sorting random method, with 53 cases in each group. Both groups were treated for 8 weeks. The clinical efficacy, efficacy of traditional Chinese medicine(TCM) syndromes, angina pectoris attacks, hemorheological indicators, inflammatory response indicators[nucleotide-binding oligomerization domain-like receptor protein(NLRP)3, interleukin(IL)-18,monocyte chemotactic protein(MCP)-1], cardiac function [cardiac output(CO), left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD), and adverse reactions after treatment were compared between the two groups.
The total effective rate and the therapeutic effect of TCM syndromes in the combined group were both higher than those in the control group(P<0.05). The duration and frequency of angina pectoris attacks, high shear viscosity of whole blood, low shear viscosity of whole blood, plasma viscosity and erythrocyte aggregation index in the combined group were all lower than those in the control group(P<0.05). The levels of NLRP3, IL-18 and MCP-1 in the combined group were lower than those in the control group(P<0.05). The improvement of CO, LVEF and LVEDD in the combined group was better than that in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).
The adjuvant therapy of Xinkang capsules can improve the clinical efficacy of CHD-SAP patients with Qi and Yin deficiency and blood stasis, effectively relieve the attack of angina pectoris, reduce the inflammatory response, improve hemorheology and cardiac function, and has a relatively high safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |